Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study

Volume: 20, Issue: 2, Pages: 458 - 460.e4
Published: Feb 1, 2022
Abstract
Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events.1Taylor F. Huffman M.D. Macedo A.F. et al.Statins for the primary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2013; 1: CD004816Crossref PubMed Scopus (604) Google Scholar Studies have shown that statins are safe among...
Paper Details
Title
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Published Date
Feb 1, 2022
Volume
20
Issue
2
Pages
458 - 460.e4
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.